We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Avery Dennison (AVY) Up 43% YTD: What's Driving the Rally?
Read MoreHide Full Article
Shares of Avery Dennison Corporation (AVY - Free Report) have been gaining on forecast-topping first-quarter 2021 results and rising demand for essential categories amid the coronavirus pandemic. The stock has gained 43%, year to date, outperforming the industry’s growth of 32.8%. The company’s focus on growing its high-value categories led by specialty labels, productivity initiatives, as well as cost-control actions has also been contributing to this price rally.
Image Source: Zacks Investment Research
Let’s delve deeper and analyze the factors driving the stock.
Earnings & Sales Top Estimates in Q1
In April, the company reported first-quarter adjusted earnings of $2.40 per share, surpassing the Zacks Consensus Estimate of $2.01. The bottom line also improved 45% year over year on significant margin expansion across all of its segments and the company’s cost-saving actions. Total revenues of $2.05 billion also beat the Zacks Consensus Estimate of $1.92 billion and increased 8.8% year over year.
Earnings Surprise History
The company has a trailing four-quarter average earnings surprise of 15.4%.
Driving Factors
Labelling of non-durable consumer goods like food, beverage, home and personal care products account for around 40% of Avery Dennison’s revenues. The company has been witnessing soaring demand for these products amid the pandemic. Over the long run, increasing demand from emerging markets on the back of rising middle class, and the consequent surge in demand for packaged goods and shift in labelling technology to pressure-sensitive materials will fuel the company’s growth. Apart from this, around 15% of its revenues is tied to logistics and shipping, which will be aided by rise in e-commerce activities.
The company’s Label and Packaging Materials segment is also well poised for growth on solid top-line performance and continued margin expansion, volume improvement, focus on high-value categories led by specialty labels, contributions from productivity initiatives as well as pandemic-driven demand for essential products.
Avery Dennison will benefit from its rapidly-growing high-value product categories, such as specialty labels and Radio-frequency identification (RFID). Continued strength in RFID and external embellishments will boost the Retail Branding and Information Solutions (RBIS) segment. Besides, the company is focused on investing in digital identification technologies. To that end, it has acquired a small software start-up ZippyYum and rolled out a Connected Product Cloud Platform start-up atma.io. The Industrial and Healthcare Materials segment is gaining from the rebound in demand for industrial products and focus on investments.
Given these factors, Avery Dennison now expects earnings per share between $8.40 and $8.80 in 2021 compared with the prior guidance of $7.65-$8.05. The mid-point of the guidance reflects year-over-year growth of 21%.
Avery Dennison has also undertaken temporary cost-containment actions to negate the impact of waning demand in some of the company’s businesses due to the pandemic. The company realized $19 million in pre-tax savings from restructuring in the first quarter. Avery Dennison anticipates incremental savings from restructuring actions, net of transition costs of roughly $70 million in the current year.
Positive Growth Projections
The company’s earnings estimate for the current year is pegged at $8.59, suggesting year-over-year growth of 20.9%.
A few other top-ranked stocks in the industrial products sector are Tennant Company (TNC - Free Report) , Encore Wire Corporation and Arconic Corporation . All of these stocks sport a Zacks Rank #1, at present.
Tennant has an expected earnings growth rate of 49.5% for the current fiscal year. The company’s shares have gained around 18% year to date.
Encore Wire has an estimated earnings growth rate of 49.5% for the current fiscal year. Year to date, the company’s shares have rallied nearly 36%.
Arconic has a projected earnings growth rate of 447% for the current fiscal year. The stock has appreciated around 21% so far this year.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Avery Dennison (AVY) Up 43% YTD: What's Driving the Rally?
Shares of Avery Dennison Corporation (AVY - Free Report) have been gaining on forecast-topping first-quarter 2021 results and rising demand for essential categories amid the coronavirus pandemic. The stock has gained 43%, year to date, outperforming the industry’s growth of 32.8%. The company’s focus on growing its high-value categories led by specialty labels, productivity initiatives, as well as cost-control actions has also been contributing to this price rally.
Let’s delve deeper and analyze the factors driving the stock.
Earnings & Sales Top Estimates in Q1
In April, the company reported first-quarter adjusted earnings of $2.40 per share, surpassing the Zacks Consensus Estimate of $2.01. The bottom line also improved 45% year over year on significant margin expansion across all of its segments and the company’s cost-saving actions. Total revenues of $2.05 billion also beat the Zacks Consensus Estimate of $1.92 billion and increased 8.8% year over year.
Earnings Surprise History
The company has a trailing four-quarter average earnings surprise of 15.4%.
Driving Factors
Labelling of non-durable consumer goods like food, beverage, home and personal care products account for around 40% of Avery Dennison’s revenues. The company has been witnessing soaring demand for these products amid the pandemic. Over the long run, increasing demand from emerging markets on the back of rising middle class, and the consequent surge in demand for packaged goods and shift in labelling technology to pressure-sensitive materials will fuel the company’s growth. Apart from this, around 15% of its revenues is tied to logistics and shipping, which will be aided by rise in e-commerce activities.
The company’s Label and Packaging Materials segment is also well poised for growth on solid top-line performance and continued margin expansion, volume improvement, focus on high-value categories led by specialty labels, contributions from productivity initiatives as well as pandemic-driven demand for essential products.
Avery Dennison will benefit from its rapidly-growing high-value product categories, such as specialty labels and Radio-frequency identification (RFID). Continued strength in RFID and external embellishments will boost the Retail Branding and Information Solutions (RBIS) segment. Besides, the company is focused on investing in digital identification technologies. To that end, it has acquired a small software start-up ZippyYum and rolled out a Connected Product Cloud Platform start-up atma.io. The Industrial and Healthcare Materials segment is gaining from the rebound in demand for industrial products and focus on investments.
Given these factors, Avery Dennison now expects earnings per share between $8.40 and $8.80 in 2021 compared with the prior guidance of $7.65-$8.05. The mid-point of the guidance reflects year-over-year growth of 21%.
Avery Dennison has also undertaken temporary cost-containment actions to negate the impact of waning demand in some of the company’s businesses due to the pandemic. The company realized $19 million in pre-tax savings from restructuring in the first quarter. Avery Dennison anticipates incremental savings from restructuring actions, net of transition costs of roughly $70 million in the current year.
Positive Growth Projections
The company’s earnings estimate for the current year is pegged at $8.59, suggesting year-over-year growth of 20.9%.
Zacks Rank & Other Stocks to Consider
Avery Dennison currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
A few other top-ranked stocks in the industrial products sector are Tennant Company (TNC - Free Report) , Encore Wire Corporation and Arconic Corporation . All of these stocks sport a Zacks Rank #1, at present.
Tennant has an expected earnings growth rate of 49.5% for the current fiscal year. The company’s shares have gained around 18% year to date.
Encore Wire has an estimated earnings growth rate of 49.5% for the current fiscal year. Year to date, the company’s shares have rallied nearly 36%.
Arconic has a projected earnings growth rate of 447% for the current fiscal year. The stock has appreciated around 21% so far this year.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>